BREAST CANCER: Aromasin Prevention reduces the risk by 65%

BREAST CANCER: Aromasin Prevention reduces the risk by 65% - ASCO-NEJM has studied to examine the aromatase inhibitor, in prevention, on healthy women, menopausal but high risk of cancer breast. It's a major announcement on June 5, at the annual meeting of the American Society of Clinical Oncology (ASCO), which has just been published in the online edition of June 4, the New England Journal of Medicine: the 'Aromasin (exemestane) reduced 65% the risk of cancer in these women particularly vulnerable.

This important clinical study, international, randomized, double-blind Phase III study by researchers at the University of Buffalo, including Professor Jean-Wactawski Wende, was conducted on over 4560 women from different sites across United States, Canada, France and Spain.

This is the first randomized study to evaluate an aromatase inhibitor as an agent for prevention of breast cancer among healthy women. The study, a follow-up duration of 3 years, concluded that in postmenopausal women at increased risk of breast cancer but who have not previously been diagnosed with breast cancer, the aromatase inhibitor called Aromasin ®, developed by Pfizer, reduces this risk by 65% compared to placebo. According to the findings of the study, the annualized incidence of women who developed cancer would 19/10.000 with exemestane vs 55 per 10,000 for the placebo group (HR: 0.35 CI 95% 0.18 to 0.70). Furthermore, no serious toxic effect and only small changes in quality of life were seen with treatment, said the NEJM article.

A very specific mode of action: Aromasin (exemestane) is already used to prevent recurrence, by thousands of women who have breast cancer, it may also be prescribed first line for women at high risk want to reduce their risk of breast cancer. Aromasin, aromatase inhibitor, has a very specific mode of action, it removes the "deep" estrogen in postmenopausal women whereas standard treatments such as tamoxifen and raloxifene are selective. The aromatase inhibitors are therefore far superior to tamoxifen in preventing recurrence in patients with early breast cancer.

These results show that exemestane can reduce, by about two-thirds the risk of cancer in postmenopausal women at high risk.

Breast Angel Breast Cancer Prevention Home Care Illumination Kit 

Source: ASCO, New England Journal of Medicine 2011

Posted in: Cancer